SOD1 and skin atrophy: The administration of a low concentration of PAPLAL also improved the skin atrophy observed in the Sod1−/− mice (the thickness of the epidermis and dermis were increased by 42.0% and 21.1%, respectively) compared with that seen in the Sod1−/− mice treated with vehicle.